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Human neural stem cells and astrocytes, but not
neurons, suppress an allogeneic lymphocyte response
Elisabet Åkesson a,b, Nina Wolmer-Solberg c, Madeleine Cederarv c,
Scott Falci d, Jenny Odeberg a,b,c,⁎a Division of Neurodegeneration, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Novum,
S-141 86 Stockholm, Sweden
b Stockholms Sjukhem, Stockholm, Sweden
c Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna,
S-171 76 Stockholm, Sweden
d Craig Hospital, Englewood, Denver, CO 80110, USAReceived 21 January 2008; received in revised form 4 June 2008; accepted 28 June 2008Abstract Transplantation of human neural stem cells (NSCs) and their derivatives is a promising future treatment for
neurodegenerative disease and traumatic nervous system lesions. An important issue is what kind of immunological reaction the
cellular transplant and host interaction will result in. Previously, we reported that human NSCs, despite expressing MHC class I
and class II molecules, do not trigger an allogeneic T cell response. Here, the immunocompetence of human NSCs, as well as
differentiated neural cells, was further studied. Astrocytes expressed both MHC class I and class II molecules to a degree
equivalent to that of the NSCs, whereas neurons expressed only MHC class I molecules. Neither the NSCs nor the differentiated
cells triggered an allogeneic lymphocyte response. Instead, these potential donor NSCs and astrocytes, but not the neurons,
exhibited a suppressive effect on an allogeneic immune response. The suppressive effect mediated by NSCs most likely involves
cell–cell interaction. When the immunogenicity of human NSCs was tested in an acute spinal cord injury model in rodent, a
xenogeneic rejection response was triggered. Thus, human NSCs and their derived astrocytes do not initiate, but instead
suppress, an allogeneic response, while they cannot block a graft rejection in a xenogeneic setting.
© 2008 Elsevier B.V. All rights reserved.Introduction
Neural stem cells (NSCs) have emerged as a promising
therapeutic tool for patients with neurodegenerative dis-
eases and traumatic injuries, such as spinal cord injury (SCI).⁎ Corresponding author. Division of Neurodegeneration, Department
of Neurobiology, Care Sciences and Society, Karolinska Institutet,
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doi:10.1016/j.scr.2008.06.002In experimental models cell therapeutic strategies have
resulted in rescue, repair, and/or replacement of injured
neural cells and tissues. A crucial step toward successful
clinical application of neural cell therapy is to unravel how
immunocompetent in vitro expanded human NSCs are,
whether a host rejection response may be induced, and
whether these cells present immunomodulatory and thereby
even neuroprotective effects after nervous system lesions.
Interestingly, NSCs expanded in vitro display dissimilarities
in the major histocompatibility complex (MHC) expression
pattern, most likely owing to different culture conditions and.
Figure 1 Cell populations included in the study. (A) A represen-
tative micrograph of a neurosphere derived from human forebrain
containing NSCs. NSCs were stained for nestin (red). (B) Neuronal
cultures stained for β-tubulin III (green). Inset: β-tubulin III (green)
and nestin (red). (C) Astrocyte cultures were stained for GFAP
(green). Inset:GFAP (green) andnestin (red). In all sections,Hoechst
nuclear stain was applied (blue). Scale bars, 25 μm.
57Human NSCs and astrocytes suppress lymphocyte responsespecies origin. Newly isolated cells from the human central
nervous system (CNS) express low levels of MHC class I and class
II expression (Åkesson et al., 2000). While we have previously
shown that both MHC class I and class II are induced upon in
vitro culture of human NSCs (Odeberg et al., 2005), Al Nimer et
al. (2004) reported only MHC class II expression, despite similar
culture conditions and cell source. The MHC class I expression
seems to be positively regulated by leukemia inhibitory factor
(LIF) (Wright et al., 2003), which might explain the relatively
high expression of MHC on our NSCs, since they are cultured
with ciliary neurotrophic factor (CNTF) which belongs to the
same cytokine family (the interleukin 6 family) as LIF. The
expression of MHC class I and class II on NSCs is induced and/or
further increased by IFN-γ treatment (Odeberg et al., 2005;
Poltavtseva et al., 2002;Wright et al., 2003). In contrast,mouse
NSCs were reported not to express either MHC class I or class II
(Hori et al., 2007; Mammolenti et al., 2004), while rat NSCs
express only MHC class I (McLaren et al., 2001). The presence of
MHC class I and class II molecules on human NSCs implies a risk
for recognition by alloreactive T cells after transplantation,
thus indicating a potential risk for immunological rejection due
to MHC incompatibility and subsequent requirement of
immunosuppressive treatment to avoid rejection.
The disadvantages of using immunosuppressive treatment
include an increased risk for opportunistic infections (Garrido
et al., 2006), toxic side effects (Rezzani, 2006), and potential
negative effects on donor cells. Recently, cyclosporin was found
to reduce cell proliferation and affect differentiation to favor
astrocytogenesis of rat neural stem cells in vitro (Guo et al.,
2007).However, cyclosporin has also been successfully provenas
a neuroprotective drug in SCI (Alonso et al., 1995; Curtis et al.,
1993; Diaz-Ruiz et al., 2005; Ibarra et al., 2007) and by blocking
the activity of romatase, a calcineurin-independent enzyme
(Sosa et al., 2005; Wei et al., 2004). In contrast, cyclosporin
treatment after transplantation of NSCs to the brain lacked an
association with improved function or increased graft survival
(Modo et al., 2002; Schwarz et al., 2006).
Despite the expression of MHC on human NSCs, they are not
recognized by alloreactive lymphocytes in vitro (Odeberg et
al., 2005). However, the in vivo situation offers
the transplanted human NSCs a more complex milieu, such as
exposure to a variety of pro- and anti-inflammatory cytokines
(Ishii et al., 2006; Nakamura et al., 2003) following a
neurotrauma that may change their immunocompetence.
Another issue to consider is the maturation and differentiation
that occur within the host that may also affect the immuno-
genicity and possible immunomodulatory potential.
In this study, the expression of immunological proteins,
the immunogenicity, and the possible immunomodulatory
potential of human NSCs versus more differentiated neural
cell populations were investigated to gain further insight of
relevance for the development of neural cell therapies.
Results
Expression of MHC molecules on NSCs, astrocytes,
and neurons
Here, we further investigated the expression of MHC class I
and II molecules on NSCs and more differentiated neuronal
and astrocyte cultures. The NSCs in the neurosphere cultures
58 E. Åkesson et al.expressed CD133 (N70%) (data not shown) and nestin (N90%,
Fig. 1A) to a high degree. After 7 days of culture under
differentiation conditions, the majority of the cells in the
neuronal cultures were immunoreactive (IR) for both NeuN
and β-tubulin III (78±12 and 59±25%, respectively; Fig. 1B).
Fewer than 10% of the cells in the neuronal cultures were IR
for glial fibrillary acidic protein (GFAP) or CD133, and 20–
30% of the cells were IR for nestin (Fig. 1B, inset). The
majority of the cells in the astrocyte cultures were IR for GFAP
(70±14%; Fig. 1C), and only a minority expressed β-tubulin III
(13±55%). In addition, amajority of theGFAP-expressing cells
was also positive for nestin at this time point (Fig. 1C, inset).
Seven days after the onset of the differentiation, we
analyzed the cells for the expression of MHC class I and class
II molecules on the cell surface. While differentiation into
astrocytic phenotypes did not alter the number of cells
expressing these molecules, a significant reduction was
demonstrated on cells in the neuronal cultures. Both the
percentage of cells IR for MHC class I and class II and the levelFigure 2 The expression of MHC class I and class II molecules. NSC
surface expression of MHC by flow-cytometric analysis. The percenta
as the mean fluorescence intensity (MFI; B and D, respectively), is sh
ANOVA. (E) The histograms show one representative example of MHC c
or neuronal cultures (isotype shown as black histograms).of expression (mean fluorescence intensity; MFI) were
significantly reduced upon differentiation into neurons
(Fig. 2). There were no differences between cases in the
expression patterns of MHC molecules due to the first
trimester gestational ages included in the study (data not
shown), as also previously reported (Piao et al., 2006).
Phenotypic characterization of the MHC-expressing
cells
To investigate further what type of cells in the human NSC,
astrocyte, and neuron cultures expressed MHC molecules on
their cell surface, we double stained the cells for MHC and
the cellular markers GFAP, β-tubulin III, and CD133 prior to
analysis by flow cytometry. The results from these experi-
ments clearly show that NSCs (CD133 IR cells) and astrocytes
(GFAP IR cells) do indeed express MHC class I and class II
molecules on the cell surface (Fig. 3). The majority of the
neurons (β-tubulin III IR cells) were also expressing MHC class Is, neuronal, and astrocyte cultures were examined for the cell-
ge of cells expressing (A) MHC class I and (C) MHC class II, as well
own. Mean values±SEM (n=5 different donors/group). ⁎Pb0.05,
lass I or class II molecule expression on cells from NSC, astrocyte,
Figure 3 Characterization of the MHC-expressing cells. Two-color flow-cytometric analysis of MHC expression on NSCs or cells from
neuronal or astrocyte cultures. Each dot plot represents 10,000 cells. The percentages of cells expressing MHC class I or II and one of
the cell-specific markers CD133, GFAP, and β-tubulin III are presented.
59Human NSCs and astrocytes suppress lymphocyte responsemolecules (Fig. 3), but lacking MHC class II molecules. A small
population of the cells in the neuron cultures was β-tubulin III
negative, butMHCclass Imolecule positive (Fig. 3). In addition,
a small percentage of MHC class II IR cells was observed in the
neuron cultures that were coexpressing CD133 (Fig. 3), most
likely representing immature cells (NSCs) still present in the
neuronal cultures. Thus, human in vitro expanded NSCs,
astrocytes, and neurons do express MHC class I molecules,
while MHC class II is present on NSCs and astrocytes.
The majority of NSCs and astrocytes, but not
neurons, express the adhesion markers lymphocyte
function-associated antigen-3 (LFA-3) and
intercellular adhesion molecule-1 (ICAM-1)
To analyze further the potential of NSCs, astrocytes, and
neurons to elicit an immune response after transplantation, we
examined the expression of the adhesion markers LFA-3 and
ICAM-1 and the costimulatorymolecules CD80, CD86, and CD40
using flow cytometry. Neither astrocytes nor neurons were
CD80 or CD40 positive, but sparse CD86 expression was found
on a small population of both neurons and astrocytes (11±8 and4±2%, respectively). Neither of the costimulatory molecules
was detected on NSCs (data not shown).
In contrast to the costimulatory molecules, the majority of
NSCs and astrocytes expressed the adhesion molecules LFA-3
and ICAM-1 on their cell surfaces (Fig. 4). Upon differentiation
into neurons the percentage of cells IR for the adhesion
markers was significantly reduced (Fig. 4A). Interestingly,
astrocytes expressed enhanced levels (MFI) of ICAM-1 com-
pared to the NSCs (Fig. 4B).
Neither NSCs, astrocytes, nor neurons trigger an
allogeneic lymphocyte reaction
We have previously shown that despite high expression of both
MHC class I and class II molecules on NSCs, they were unable to
elicit a proliferative immune response (Odeberg et al., 2005).
Therefore, we were also interested in investigating the
immunogenicity of human NSC-derived astrocytes and neurons.
A proliferative responsewas not demonstratedwhen allogeneic
lymphocyteswere stimulatedwith NSCs, neurons, or astrocytes
in mixed lymphocyte culture (MLC) assays (Fig. 5A). The
immunogenicity of the cells was not affected by treatmentwith
Figure 4 The presence of the adhesion molecules ICAM-1 and
LFA-3 on NSCs, astrocytes, and neurons. Cells were examined for
the expression of ICAM-1 and LFA-3 by flow cytometry, and (A) the
percentage of cells and (B) the MFI are shown. The values
represent means±SEM (n≥4 different donors/group). §Pb0.05,
compared to both NSC and astrocytes (§1, ICAM-1, and §2, LFA-3).
⁎Pb0.05.
Figure 5 Neither NSCs, neurons, nor astrocytes trigger a
lymphocyte proliferative response. (A) Cells from neuronal and
astrocyte cultures as well as NSCs were cultured together with
allogeneic PBMCs. Differentiated cells were also treated with
IFN-γ. The proliferative lymphocyte response was measured as
counts per minute (cpm). As positive control PBMCs were
stimulated with noncompatible allogeneic PBMCs (allo) and as
negative control, PBMCswere stimulatedwith themselves (auto).
The values are means±SEM (PBMCs and neural cells have nN3
different donors/group). (B) The surface expression of MHC class I
and class II molecules before (filled curve) and after IFN-γ (black
line) treatment is shown (one representative example). §Pb0.05
(ANOVA) compared to all other groups presented in graph.
60 E. Åkesson et al.the inflammatory cytokine IFN-γ (Fig. 5A), despite increased
levels of MHC class I and class II molecule expression induced by
the IFN-γ treatment (Fig. 5B). Thus, neither NSCs, neurons, nor
astrocytes triggered a proliferative Tcell response.
NSCs and astrocytes suppress lymphocyte
proliferation induced by alloantigen
To characterize whether our NSCs and differentiated cells had
the ability to modulate a human allogeneic immune response,
we stimulated peripheral blood mononuclear cells (PBMCs)
with alloantigen in the presence or absence of NSCs or
differentiated cells (neurons or astrocytes). NSCs clearly
inhibited lymphocyte proliferation induced by alloantigen and
at a NSC:PBMC ratio of 1:1 a complete suppression was seen
(Fig. 6A). Astrocytes, but not neurons, did also interfere with
alloantigen stimulation of lymphocytes (Fig. 6B) at equivalent
cell ratios. The capacity of NSCs to suppress a lymphocyte (T
cell) response was further investigated by stimulation of
lymphocytes with the T cell mitogens phytohemagglutinin
(PHA) and concanavalin A (Con A) in the presence or absence of
NSCs. Interestingly, NSCs did not interfere with either PHA or
ConA stimulation at the ratios 1:10 and 1:1. However, when the
cell concentration of NSCs was increased even further (5:1),
PHA but not Con A activation was suppressed (Fig. 6C).NSCs can mediate their inhibitory effect via several
different mechanisms, such as release of soluble factor or
cell–cell interactions. Soluble factors can be either released
continuously from NSCs or induced upon the cell–cell interac-
tion and be secreted by either NSCs or lymphocytes. To analyze
whether NSCs release soluble factors that suppress an
alloantigen stimulation of lymphocytes, we stimulated PBMCs
with alloantigens in the presence or absence of supernatant
from NSC cultures, which did not affect lymphocyte prolifera-
tion (Fig. 6D). In addition, we analyzed the supernatant from
Figure 6 Lymphocyte stimulation by alloantigens is suppressed by human NSCs and astrocytes. PBMCs were stimulated with
alloantigens (allo) in the presence or absence of (A) NSCs or (B) cells from neuronal or astrocyte cultures. The cell concentration ratios
(neural cells:PBMCs) testedwere 1:10 and 1:1. As a negative control PBMCswere also stimulated with themselves (auto). The values are
means±SEM (n=6/group). In (C), human PBMCswere stimulatedwith themitogens PHA and Con A, in the presence or absence of NSCs at
different cell concentrations (NSCs:PBMCs ratio 1:10, 1:1, and 5:1) (mean values±SEM (n=6/group)). (D) PBMCs were also stimulated
with alloantigen in the presence or absence of supernatant from NSC cultures (means±SEM (n=6/group)). In all individual experiments
run, PBMCs and neural cells were derived from at least three different donors/cases. ⁎Difference between groups, pb0.05 (ANOVA).
61Human NSCs and astrocytes suppress lymphocyte responsealloantigen stimulation in the presence or absence of NSCs,
after 72 h incubation, for the presence of IL-2, IFN-γ, IL-10, and
TGF-β, of which the latter two are known to suppress T cell
proliferation. The supernatants from lymphocytes stimulated
with alloantigen in the presence of NSCs did not display
elevated levels of either IL-10 or TGF-β (data not shown).
Furthermore, they contained levels of IL-2 and IFN-γ similar
to those of lymphocytes stimulated with alloantigens in
the absence of NSCs (data not shown). Furthermore, human
PBMCs were stimulated with incompatible PBMC populations
with or without conditioned medium from NSC cultures to
evaluate whether the suppressive factor(s) were soluble.
No suppression was observed of an allogeneic response
under these conditions (Fig 6 D).Thus, these results in-
dicate that the suppressive effect mediated by NSCs on
the lymphocyte proliferative response is dependent on cell–
cell contact rather than on the investigated soluble factors
alone.Human NSCs trigger a rejection response in a
xenograft model
With low and even suppressive immune actions by the human
NSCs in the in vitro allo-experiments, we investigated the
immunogenicity of these cells further in vivo, in a xeno-
transplantation model in the SCI rodent. Six different
experimental groups were included, with five animals/
group. One animal presented weight loss early after surgery
and was thereby excluded from the study. The survival of
human neural cells deriving from the transplanted neuro-
spheres was analyzed by immunohistochemistry using
human-specific HSP27 antibodies (Fig. 7). All the immuno-
suppressed cyclosporin A (CSA)-treated rodents included
numerous HSP27-IR cells in their spinal cord parenchyma at 6
weeks posttransplantation. However, in the saline-treated
groups only three rodents presented human cells at this time
point and they were all grafted with the P0 human NSCs,
Figure 7 Rejection response after xenotransplantation of
human NSCs to acute and severe SCI. (A) The number of rodents
presenting surviving xenografted human HSP27+ cells in their
spinal cord per total number of cases with intraspinal lesion/
transplantation. (B) The human NSC graft length in the rodent
host spinal cord at 6 weeks posttransplantation. ⁎pb0.05,
ANOVA, n=5/group. CSA, cyclosporin A; P0 graft, human NSC
graft derived from passage 0 neurosphere cultures; P5 graft,
derived from passage 5 neurosphere cultures.
62 E. Åkesson et al.known to express low levels of MHC molecules (Fig. 7A). No
significant difference in human graft length, in the rostro-
caudal direction, was observed between the CSA-treated
groups (mean lengths 3.4±0.9 and 4±0. 8 mm, respectively)
and the saline-treated groups with P0 NSCs (mean length of
2.1±1. 1 mm) (Fig. 7B). However, the saline-treated rodents
with P5 NSC grafts presented no surviving cells at all
(Fig. 7B). Thus, the human NSCs trigger a rejection response
in the xenograft model when no CSA is administered.
However, donor-dependent factors that change with in
vitro culture from P0, when the neurospheres just formed,
to P5 of the human NSCs seem to play a role in the degree of
xenograft rejection response.
Discussion
During the past decade the potential use of NSCs in cell
therapy for patients with neurodegenerative disease or
trauma has increased, due to the cells' capacity to multiply
and differentiate in vitro (Gage, 2000), providing a sufficient
donor supply for transplantation. Moreover, transplantationof neural cells has resulted in functional recovery in a
number of different CNS disorders (Bjorklund and Lindvall,
2000; Lindvall and Bjorklund, 2000; Lindvall et al., 1990),
and human NSCs survive, migrate, differentiate, and interact
with the adult lesioned CNS to improve host function
(Akiyama et al., 2001; Fricker et al., 1999). We have studied
the immunocompetence of human NSCs, and their derived
astrocytes and neurons, of relevance to the development of
cell therapies. We report that in vitro-expanded human NSCs
and astrocytes express MHC and do not trigger, but in
contrast inhibit, an allograft response.
The presence of MHC class I and II molecules on astrocytes
and NSCs, but not neurons, would in theory indicate a risk for
rejection after transplantation. However, neither NSCs nor
differentiated cells were recognized by alloreactive lym-
phocytes, confirming our previous study regarding the
immunogenicity of NSCs (Odeberg et al., 2005). Treatment
with the inflammatory cytokine IFN-γ did not increase the
immunogenicity of cells. Lack of rodent NSC immunogenicity
is known (Hori et al., 2007; Yu et al., 2006), while contrasting
results with human NSCs that triggered lymphocyte prolif-
eration in one-way-mixed lymphocyte reactions were
recently reported (Ubiali et al., 2007). The lack of MHC
class II expression and lower expression of MHC class I on
neurons are consistent with previous data from others
(McLaren et al., 2001; Modo et al., 2003). Double staining
revealed that astrocytes indeed express MHC class I and class
II molecules, while neurons express only detectable levels of
MHC class I. Furthermore, while the majority of NSCs and
astrocytes expressed the adhesion molecules LFA-3 and
ICAM-1, these molecules were present on only a fraction
(10%) of cells from the neuronal cultures.
The lack of an alloreactive lymphocyte response led us
further to investigate whether our neural cells had the
potential to interfere with and modulate the activation of
lymphocytes, in accordance with the properties of mesench-
ymal stem cells, as well as certain subpopulations of
astrocytes (Jones et al., 2007; Le Blanc et al., 2003;
Matsumoto et al., 1993; Sun et al., 1997). Indeed, human
NSCs and newly formed astrocytes, but not neurons,
suppressed lymphocyte stimulation to alloantigens, suggest-
ing low risk for alloreaction and a role as immunomodulators.
These characteristics of NSCs add to their role as a cell
replacement by also protecting the lesioned CNS from
inflammatory damage, the “bystander” effect (Ourednik
et al., 2002; Pluchino and Martino, 2008). In accordance,
mouse NSCs reduced CNS inflammation and were proven to
be neuroprotective under syngeneic transplantation condi-
tions in experimental autoimmune encephalitis (Pluchino et
al., 2005; Einstein et al., 2007). This immunomodulatory
property seems to be a common denominator of not only
pluri- and multipotent, undifferentiated cells, since adult
stromal cells (Jones et al., 2007) in addition to embryonic
stem (ES), mesenchymal, and hematopoietic stem cells (Di
Nicola et al., 2002; Li et al., 2004; Rasmusson et al., 2005),
present similar functions. Like ES, mesenchymal, and
hematopoietic stem cells, our human NSCs may block both
allogeneic and mitogen-induced stimulation, provided that
the number of cells is sufficient. The maturation stage may
also play a part. Our differentiated cells are still relatively
immature, with a majority of GFAP-IR cells double stained for
nestin. The mechanisms by which these various cells exert
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and may be diverse.
Thus, our study indicates that human NSCs possess
features that counteract an immune response, providing
protection in the allogeneic situation, by inhibition of a
lymphocyte response. This suppressive effect may depend on
a cell–cell interaction between lymphocytes and human
NSCs since supernatant from NSC cultures did not inhibit
lymphocyte proliferation. Furthermore, the inhibition was
not due to increased production of IL-10 and TGF-β, further
supporting that the effect mediated by NSCs on the
lymphocyte proliferative response is dependent on cell–
cell contact rather than on these soluble factors.
The inhibition of an inflammatory response by neural
precursor cells in vivo may in fact act both in the CNS (Yu et
al., 2006) and as a peripheral immunosuppression elicited
from grafted neural precursor cells in the lymph nodes and
spleen, counteracting experimental autoimmune encephali-
tis (Ben-Hur, 2007; Einstein et al., 2006). A challenge is now
to understand and regulate this immunomodulation by the
donor cells and to investigate during what time window these
properties are most effective in the injured nervous system
to reduce the need for immunosuppressive drugs and to
achieve neuroprotection.
In vitro studies allow human allograft models to be
scrutinized, while investigating a complex and full host
response in vivo may only be performed in the xenograft
situation. The two are significantly diverse host–graft
models. A majority of in vivo xenograft models, including
human fetal neural donor cells (non-in vitro-expanded),
demonstrate rejection of the human donor cells (Barker et
al., 2000; Finsen et al., 1991; Mason et al., 1986) and
similarly human NSCs grafted to a traumatic brain injury
required immunosuppressive treatment (Al Nimer et al.,
2004; Ortega et al., 1992; Wennersten et al., 2006). We here
report that our human NSCs, unable to trigger an alloreac-
tion, induce a xenoreaction resulting in graft rejection.
However, donor-dependent factors that change with in vitro
culture from P0 to P5 of the human NSCs seem to play a role
in the strength of the xenograft response. We know that MHC
class I and II molecules substantially increase between those
in vitro passages and may explain the lack of surviving human
cells in the case of P5 NSC xenografts treated with saline
alone. This implies that in vitro-expanded long-term
cultured human NSCs may exhibit an increased risk for
rejection in an allotransplantation. Therefore, the knowl-
edge of how to reduce/regulate these donor-dependent
factors after long-term in vitro expansion is required, to gain
sufficient cell numbers for cryostorage, safety tests, and
clinical application.
In the few studies investigating the immunological
response to transplanted NSCs in an allogeneic situation in
animal species divergent results have been achieved and
therefore are difficult to interpret for the human clinical
setting. Hori et al. (2007) demonstrated that allogeneic
mouse CNS progenitor cells transplanted beneath the kidney
capsule were not rejected, suggesting that the cells lack
immunogenicity, supporting our in vitro data. In contrast,
transplantation of allogeneic rat NSCs into traumatized brain
was associated with increased infiltration of T cells to the
site of transplantation compared to lesion alone (Zheng et
al., 2007). The different results may reflect NSC speciesdifferences, as well as a difference in MHC expression, and/
or that the immune response is more alert/prone to become
activated in traumatized compared to normal animals. If NSC
expression of MHC is the major factor for an acceptance or
rejection response, human NSCs should be more prone to
triggering a strong immune response and become rejected,
since they are reported to have both MHC class I and class II
(Åkesson et al., 2000; Al Nimer et al., 2004; Odeberg et al.,
2005; Poltavtseva et al., 2002; Wright et al., 2003), whereas
mouse and rat NSCs lack or express only low levels of MHC
class I molecules (Hori et al., 2007; Mammolenti et al., 2004;
McLaren et al., 2001).
In summary, human NSCs, neurons, and astrocytes all
exhibit relatively low immunogenicity. Furthermore, NSCs
and astrocytes have the potential to modulate an immune
response, which may favor successful cell therapy for
patients with neurodegenerative diseases, traumatic inju-
ries, or stroke in the future. However, further research is
required to fully understand and regulate the interaction
between transplanted NSCs and the host immune system.
Materials and methods
Human forebrain tissue and peripheral blood
mononuclear cells
After obtaining informed consent from the pregnant women
and approval by the Regional Human Ethics Committee,
Stockholm, we collected subcortical forebrain tissue from
human abortion material of 5–12 weeks of gestation, as
previously described (Odeberg et al., 2005; Piao et al.,
2006).
After approval by the Regional Human Ethics Committee,
Stockholm, human PBMCs were purified from buffy coats
from healthy blood donors (provided by the Karolinska
University Hospital blood center), using Lymphoprep (Axis-
Shield PoC AS) according to the manufacturer's instructions.
Establishment of human neurosphere cultures
The samples of human tissues were dissociated mechanically
into single-cell suspensions employing a glass–Teflon homo-
genizer, following which neurospheres were established and
propagated as previously described (Åkesson et al., 2007;
Odeberg et al., 2005, 2006, 2007; Piao et al., 2006). The
neurospheres were passaged every 7–10 days, using TrypLe
(Invitrogen, Life Technologies). Herein, we refer to cultured
human neural cells expanded as free-floating neurospheres
as NSCs.
Differentiation of NSCs
The neurospheres were dissociated into a single-cell suspen-
sion and suspended either in Neurobasal medium supplemen-
ted with B27 (Invitrogen Life Technologies) or in DMEM:F12
supplemented with 0.6% glucose, 5 mM Hepes, 1% N2
supplement, and 10% fetal calf serum (FCS). Neurobasal
medium promotes NSC differentiation primarily to neurons,
whereas the medium containing 10% FCS promotes the
differentiation primarily to astrocytes. Cells were seeded
onto poly-d-lysine (Sigma, 0. 1 mg /ml)-coated wells (6-
64 E. Åkesson et al.wells/plate; Nunc) at a cell concentration of 240×103 cells/
well. Cells were also seeded onto poly-d-lysine-coated
circular glass coverslips in 24-well plates (Nunc) at a cell
concentration of 60,000 cells/ml (neuronal cultures) or
30,000 cells/ml (astrocyte cultures). After 7 days of
differentiation, immunocytochemical, flow-cytometric, or
immunological assays were performed as described below.
Flow-cytometric analysis
A fluorescence-activated cell sorter (FACSort; Becton–Dick-
inson) was used to analyze the NSCs, neurons, or astrocytes
for the expression of human leukocyte antigen (HLA) class I
(clone W6/32, Dakopatts), HLA-DR (clone L243), CD80, CD86,
LFA-3, and ICAM-1 PE (all purchased from BD Bioscience) and
CD133 (Miltenyi Biotec). The isotype controls used were as
follows: IgG2a PE or FITC, IgG1 FITC, IgG1, and IgG2b
(Dakopatts). The cells were stained with the respective
antibodies at 4 °C for 30 min, washed, and resuspended in
phosphate-buffered saline (PBS). Only the viable cells,
propidium iodide negative, were analyzed using CELLQuest
software (Becton–Dickinson Immunocytometry Systems).
For intracellular staining, cellswere fixedandpermeabilized
withCytofix/Cytoperm (BDBiosciences) and stainedwith one of
the polyclonal antibodies GFAP (rabbit; Dakopatts), nestin
(Chemicon), and β-tubulin III (Biosite) or with the respective
isotype control. Following rinsing, the cellswere incubatedwith
the appropriate secondary antibody (either Alexa Fluor 488
(1:600; Molecular Probes) or Cy3 (1:1200; Jackson ImmunoR-
esearch Laboratories)) and analyzed as above.
For cell samples double stained for cell-surfacemarkers and
intracellular markers, cells were first stained for the cell-
surface molecule, thereafter fixed/permeabilized, and then
stained for the intracellular molecule. In these experiments
both single anddouble stainswereperformed to correct for the
risk of false double labeling.
Mixed lymphocyte cultures
NSC, astrocyte, or neuronal cultures were harvested (N90% of
the cells were viable as demonstrated with trypan blue),
followed by dilution in RPMI medium with 10% FCS. The cells
were irradiated (20 Gy; Gammacell 2000, Molsgard, Denmark),
and 5×104 cells were cocultured with PBMCs (105 cells), in
200 μl medium in 96-well plates, and incubated at 37 °C and 5%
CO2. As a positive control, the PBMCswere also stimulatedwith
alloantigen, i.e., irradiatedPBMCs fromanother donor, amixed
lymphocyte reaction culture. At 5 days poststimulation, the
cells were pulsed with 1 μCi [methyl-3H]thymidine (Amersham
Life Science). The following day, the cells were harvested onto
filters, using a plate harvester (Harvester 996; Tomtec,
Hamden, CT, USA) according to the manufacturer's instruc-
tions, and counted in an automated radioactivity counter (1450
MicroBeta Trilux, Wallac, Sweden AB). The stimulated prolif-
eration was calculated as the mean counts per minute of
triplicate samples.
To study the effects of NSCs, neurons, and astrocytes on
lymphocyte reactivity in MLCs, PBMCs (105 cells) were
stimulated with an equal number of irradiated PBMCs from
another donor. A third part of irradiated NSCs or differentiated
cells was added at the beginning of the experiment, at a cell
concentration of 1×104 cells/well (1:10 dilution). In the dose–response experiments, neural cells (NSCs or differentiated
cells) were added at a neural cell:PBMC ratio of 1:10 and 1:1.
These experiments were performed with human NSCs and
PBMCs from at least three different donors.
MLC in the presence of supernatant from irradiated NSCs
PBMCs were stimulated with allogeneic PBMCs (as described
above) in the presence or absence of supernatant from
irradiated NSCs. The supernatant was prepared as follows:
NSCs were irradiated and 0.5×106 cells/ml were incubated
for 6 days. Thereafter the supernatant was harvested,
cleared by centrifugation, and then added to the MLC
assay. The plates were harvested as described above.
IFN-γ treatment
NSC, neuron, or astrocyte cultures were treated with either
IFN-γ (R&D Systems; 200 U/ml) or vehicle (RPMI with 10%
FCS), as a control, for 3 days prior to further experiments.
Mitogen stimulation
PBMCs (5×104 cells/well) were stimulated with PHA (5 μg/ml)
or Con A (20 μg/ml) (both from Sigma) in triplicates, in the
presence or absence of irradiated NSCs at the following NSC:
PBMC ratios: 1:10, 1:1, and 5:1. The cultures were pulsed with
1 μCi [methyl-3H]thymidine (Amersham Life Science) at 2 days
poststimulation. The day after, cells were harvested onto
filters as described above.
Experimental animals and surgical procedure
Thirty female Harlan Sprague–Dawley rats, 170–190 g (B-land,
Denmark) were included in the study. The experimental
procedure was approved by The Experimental Animal Ethics
Committee of Southern Stockholm, Huddinge Tingsrätt. The
following experimental groups were included in the study: (1)
CSA-treated rodents with a spinal cord lesion alone, (2) CSA-
treated rodentswith a spinal cord lesion and passage (P) 0, NSC
graft, (3) CSA-treated rodents with a spinal cord lesion and P5
NSC graft, (4) saline-treated rodents with a spinal cord lesion
alone, (5) saline-treated rodents with a spinal cord lesion and
P0 NSC graft, and (6) saline-treated rodents with a spinal cord
lesion and P5 NSC graft. For a detailed description of the
surgical procedure, see the supplementary materials and
methods. At 42 days postsurgery the animals were reanesthe-
tized and perfusion fixed through the ascending aorta with
100 ml Ca2+-free Tyrode's solution, followed by 400 ml
phosphate-buffered 4% paraformaldehyde (Merck, Darmstadt,
Germany). The tissue was postfixed for 90 min and cryopre-
served in 20% sucrose in 0. 1 M PBS at 4°C for at least 48 h.
Immunocytochemistry
Human neurospheres were fixed and like the rodent spinal
cords cryosectioned at 5 or 10 μm thickness, respectively, as
previously described (Piao et al., 2006; Åkesson et al., 2007).
The differentiated cells present on the glass coverslips were
fixed with buffered 4% paraformaldehyde 4, for 15 min at
room temperature, and thereafter both sections and cells
were preincubated with 1.5% normal goat serum for 30 min
prior to incubation with the primary antibodies. The
following antibodies were used: nestin (1:200, mouse, or
65Human NSCs and astrocytes suppress lymphocyte response1:400, rabbit; both from Chemicon), GFAP (1:500; Dako-
patts), β-tubulin III (1:800, mouse; Chemicon), NeuN (1:100,
mouse; Chemicon), and human specific heat shock protein 27
(HSP27, 1:1000; Nordic Biosite).
The staining procedure was performed as previously
described (Odeberg et al., 2005; Piao et al., 2006).
Visualization of the primary antibodies was achieved by
incubation with secondary antibodies conjugated to Alexa
Fluor 488 (Molecular Probes; diluted 1:400) or Cy3
(Jackson ImmunoResearch Laboratories; diluted 1:1800).
The cell nuclei were stained with Hoechst (1 μg/ml;
Molecular Probes) prior to the coverslips being mounted
with PVA-DABCO (9.6% polyvinyl alcohol, 24% glycerol, and
2.5% 1,4-diazabicyclo (2.2.2) octane in 67 mM Tris–Cl,
pH 8.0).
The images were examined in a fluorescence micro-
scope (Zeiss; Axiophot) and documented using a CCD
camera (Hamamatsu; ORCA-ER, C4742-95) together with
the Openlab software for Macintosh (Improvision). The
number and/or percentage of cells expressing the differ-
ent antigens analyzed was calculated by counting three
fields per glass (objective 20×). The microscopy of the
intraspinal transplantation was performed blindly with
coded slides. The human graft length was estimated by
multiplying the number of host spinal cord cross sections
(with human HSP27+ cells present) with the section
interval of 0. 4 mm.
Quantification of cytokines
Supernatants from PBMCs stimulated with alloantigens for 72 h
in the presence of NSCs (1:10 NSC:PBMC ratio) were collected,
cleared by centrifugation, and frozen (−70 °C) for cytokine
analysis. Flow Cytomix (Bender MedSystems GmbH) was used
to measure the levels of IFN-γ, TGF-β, IL-10, and IL-2, and the
data were analyzed with FlowCytomixPro 2.2 software.
Statistical analyses
Analysis of possible differences in the size of the cell
populations, degree of fluorescence intensity, proliferation
response, and human NSC graft length between various groups
was performed by multifactorial analysis of variance (ANOVA).
Sheffe's test was employed as post hoc test. p valuesb0.05
were considered significant. The mean values±SEM are
presented in the figures and text. The statistical program
Statview 4.12, for Macintosh computers, was used for
statistical analysis (Abacus Concepts, Berkeley, CA, USA).
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